Patent directory · USPTO A61K / A61P
Patents matching “SION”
1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12378558
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
granted -
US 12377151
Immobilized endoglycosidase fusion protein and use thereof
granted -
US 12378540
Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
granted -
US 12365899
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12350245
Stable oral suspensions of baclofen
granted -
US 12350285
Compounds and methods for reducing ATXN3 expression
granted -
WO 2025143118
COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT D'UNE LÉSION DE LA MOELLE ÉPINIÈRE ET PROCÉDÉ DE PRODUCTION D'UN MODÈLE ANIMAL DE PRIMATE NON HUMAIN POUR UNE LÉSION DE LA MOELLE ÉPINIÈRE
granted -
US 12343357
Compositions and methods for modulating MECP2 expression
granted -
US 12343380
Expansion of TILs utilizing AKT pathways inhibitors
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12329816
Immunotherapy with metabolic enzyme expression
granted -
US 12331078
Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same
granted -
WO 2025121445
POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2
granted -
WO 2025120866
POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2
granted -
US 12325691
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12310992
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
granted -
US 12304930
Prefusion-stabilized hMPV F proteins
granted -
US 12297431
Modulation of huntingtin expression
granted -
US 12291709
Compositions and methods for modulating apolipoprotein (a) expression
granted